These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19076563)

  • 21. Omalizumab and other new drug therapies occupy a small space in asthma disease management.
    Curtiss FR
    J Manag Care Pharm; 2009 Apr; 15(3):289-93. PubMed ID: 19326961
    [No Abstract]   [Full Text] [Related]  

  • 22. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.
    Bousquet J; Siergiejko Z; Swiebocka E; Humbert M; Rabe KF; Smith N; Leo J; Peckitt C; Maykut R; Peachey G
    Allergy; 2011 May; 66(5):671-8. PubMed ID: 21255035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
    Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
    Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of omalizumab in asthma.
    Tan RA; Corren J
    Expert Opin Drug Saf; 2011 May; 10(3):463-71. PubMed ID: 21401438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab for the treatment of severe persistent allergic asthma.
    Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
    Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Better management of patients with difficult asthma].
    Humbert M
    Presse Med; 2006 Oct; 35(10 Pt 2):1492-4. PubMed ID: 17028512
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of EPR3 asthma guidelines: what's different?
    Lang DM
    Allergy Asthma Proc; 2007; 28(6):620-7. PubMed ID: 18201424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of asthma with anti-immunoglobulin E monoclonal antibody.
    Liu AH
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S24-8. PubMed ID: 16722328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
    Di Stefano F; Cinti B; Antonicelli L
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma.
    Prescrire Int; 2011 Nov; 20(121):262. PubMed ID: 22066310
    [No Abstract]   [Full Text] [Related]  

  • 40. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
    Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
    Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.